Treatment with the mTORC1 inhibitor rapamycin achieved a reduction of leukemic burden as well as prolonging survival in diseased mice implying PI3K/AKT/mTOR signaling in leukemogenesis of PTEN− acute leukemia. The gene discussed is PIK3CA; the disease is acute leukemia.